David P. Dearnaley, MD, on Prostate Cancer: Results from the CHHiP Trial
2016 Genitourinary Cancers SymposiumDavid P. Dearnaley, MD, of The Royal Marsden NHS Foundation Trust, discusses the comparison, in this study, of hypofractionated high-dose IMRT schedules for prostate cancer (Abstract 2).
Related Videos
A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance
A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in ...
Christopher J. Sweeney, MBBS: Testicular Cancer Update
Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of me...
Toni Choueiri, MD: Renal Cancer Update
Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular...
Nicholas D. James, BSc, MBBS, PhD, on Urothelial Carcinomas: Year in Review
Nicholas D. James, BSc, MBBS, PhD, of the University of Warwick, gives his expert perspective on treatment advances in urothelial cancers.
W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study
W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).<...
